ReviewAnatomical science international2025
Blood-brain barrier-penetrant AAV vectors for cell type-specific gene expression in the mouse brain.
Review in Anatomical science international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNA-7: a versatile player and core target in brain disorders.Journal of translational medicine · 2026Pooled it
- Synaptic dysfunction and adaptation after NMDA receptor ablation in the mouse medial prefrontal cortex.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Since the report in 2016 of AAV-PHP.B, a capsid variant of adeno-associated virus (AAV) capable of efficiently penetrating the mouse blood-brain barrier (BBB), numerous other BBB-penetrant capsid variants have been developed. These variants differ in their use of membrane-bound receptors expressed on vascular endothelial cells, their BBB permeability, and their tropism toward specific brain cell types. In the first half of this paper, we provide an overview of four representative BBB-penetrant AAV capsid variants-PHP.B, PHP.eB, AAV-F, and 9P31. By combining these capsids with cell type-specific promoters, it is possible to achieve transgene expression selectively in target brain cell populations via intravenous administration. In the latter half of this paper, we focus on brain cell type-specific promoters and enhancers that are compatible with AAV packaging, including those developed in our own laboratory.
Indexed as
Identifiers
40986189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.